Evidence map›Paper›PMID 41246309›Full record

ArticleFrontiers in immunology2025

TAPBPR promotes editing of the HLA-B44 peptide repertoire, increasing the presentation of peptides containing a C-terminal tryptophan.

Aure Aflalo, Arwen F Altenburg, Marcel Wacker, Esam Khanfar, Jens Bauer, Juliane S Walz, Louise H Boyle

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Aure AflaloDepartment of Pathology, University of Cambridge, Cambridge, United Kingdom.
Arwen F AltenburgDepartment of Pathology, University of Cambridge, Cambridge, United Kingdom.
Marcel WackerDepartment of Peptide-based Immunotherapy, Institute of Immunology, University and University Hospital Tübingen, Tübingen, Germany.
Esam KhanfarDepartment of Pathology, University of Cambridge, Cambridge, United Kingdom.
Jens BauerDepartment of Peptide-based Immunotherapy, Institute of Immunology, University and University Hospital Tübingen, Tübingen, Germany.
Juliane S WalzDepartment of Peptide-based Immunotherapy, Institute of Immunology, University and University Hospital Tübingen, Tübingen, Germany.
Louise H BoyleDepartment of Pathology, University of Cambridge, Cambridge, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Major histocompatibility complex class I (MHC-I) molecules play a key part in the adaptive immune response by presenting antigens to CD8

Indexed as

Antigen PresentationHLA-B44 AntigenPeptidesTryptophanCD8-Positive T-LymphocytesHumansMembrane Transport ProteinsProtein BindingHLA-B44 AntigenMembrane Transport ProteinsPeptidestapasinTryptophanantigen presentationHLAimmunopeptidomicsMHCTAPBPR

Identifiers

PMID41246309
PMCPMC12615179

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.